Fig. 4
From: GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Combination of immune checkpoint inhibitors with BsAb treatment. a In vivo anti-tumor effect of PD-1 blockades and GD2-EATs or HER2-EATs combination therapy against osteosarcoma. b Flow cytometric analyses of tumor-infiltrating lymphocytes (TILs) on day 52 (for GD2-EATs) and day 58 (for HER2-EATs) post-treatment. c Fresh-frozen tumor sections were stained with mouse IgG3-3F8, and GD2 expression was scored by staining intensity